marimastat has been researched along with artesunate in 2 studies
| Studies (marimastat) | Trials (marimastat) | Recent Studies (post-2010) (marimastat) | Studies (artesunate) | Trials (artesunate) | Recent Studies (post-2010) (artesunate) |
|---|---|---|---|---|---|
| 215 | 28 | 53 | 192 | 1 | 137 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avery, VM; Butler, GS; Drinkwater, N; Duffy, S; Grin, PM; Kassiou, M; Lucantoni, L; Malcolm, TR; McGowan, S; Overall, CM; Scammells, PJ; Vinh, NB | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
2 other study(ies) available for marimastat and artesunate
| Article | Year |
|---|---|
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
Topics: Aminopeptidases; Antimalarials; Binding Sites; Catalytic Domain; Cell Survival; Drug Resistance; HEK293 Cells; Humans; Hydroxamic Acids; Molecular Docking Simulation; Plasmodium; Protease Inhibitors; Protozoan Proteins; Structure-Activity Relationship | 2019 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |